Evidence map›Paper›PMID 36032214›Full record

ArticleResearch and practice in thrombosis and haemostasis2022

A systematic review of biomarkers among hospitalized patients with COVID-19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH.

Scott C Woller, Kerstin de Wit, Helia Robert-Ebadi, Camila Masias, Frederikus A Klok, Paul L den Exter, Pierre-Emmanuel Morange, David Castelli, John-Bjarne Hansen

Open access · goldAbstract read
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. COVID19 biomarkers: What did we learn from systematic reviews?Frontiers in cellular and infection microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 5 countries.

Scott C WollerDepartment of Medicine Intermountain Medical Center, Intermountain Healthcare Murray Utah USA.ORCID https://orcid.org/0000-0002-2522-2705
Kerstin de WitDepartments of Emergency Medicine and Medicine Queen's University Kingston Ontario Canada.ORCID https://orcid.org/0000-0003-2763-6474
Helia Robert-EbadiDivision of Angiology and Hemostasis Geneva University Hospitals and Faculty of Medicine Geneva Switzerland.ORCID https://orcid.org/0000-0003-3801-1269
Camila MasiasFlorida International University - Herbert Wertheim College of Medicine Miami Florida USA.ORCID https://orcid.org/0000-0002-1380-3799
Frederikus A KlokDepartment of Medicine - Thrombosis and Hemostasis Leiden University Medical Center Leiden The Netherlands.ORCID https://orcid.org/0000-0001-9961-0754
Paul L den ExterDepartment of Medicine - Thrombosis and Hemostasis Leiden University Medical Center Leiden The Netherlands.ORCID https://orcid.org/0000-0002-1543-5731
Pierre-Emmanuel MorangeAix Marseille Univ Marseille France.ORCID https://orcid.org/0000-0002-9065-722X
David CastelliLibrary Sciences Intermountain Healthcare Murray Utah USA.ORCID https://orcid.org/0000-0002-5818-6974
John-Bjarne HansenUniversity of Tromsø, University Hospital of North Norway Tromsø Norway.ORCID https://orcid.org/0000-0003-4854-3162
Intermountain Healthcare · USLeiden University Medical Center · NLAix-Marseille Université · FRFlorida International University · USQueen's University · CAUniversity Hospital of North Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Thrombosis is reported to occur more often among patients with COVID-19 than otherwise expected in the setting of viral pneumonia and sepsis. Systemic inflammatory biomarkers may be associated with venous thromboembolism (VTE) risk. The ISTH subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease aimed to report the evidence on prognostic biomarkers for VTE in hospitalized patients with COVID-19. Methods: Using a standardized Preferred Reporting Items for Systematic Reviews and Meta-analysis methodology, we conducted a systematic literature review to identify studies reporting prognostic biomarkers for VTE among hospitalized patients with COVID-19. Eligible studies included adults hospitalized with COVID-19 and reported the prognostic associations between any biomarker measured on admission, and the subsequent diagnosis of deep vein thrombosis or pulmonary embolism. Two authors reviewed titles and abstracts, and three authors extracted study data and performed review of bias. Results were displayed descriptively. Meta-analysis was not possible. Results: From the initial 196 identified studies, full-text review was performed for 72 studies. Admission D-dimer levels were associated with VTE during hospitalization in five studies, and elevated platelet count was associated with VTE during hospitalization in one study. The risk of bias ranged from low to high for included studies. Overall, there was a paucity of high-quality prognostic studies. Studies on other biomarkers did not meet the systematic review inclusion criteria. Conclusions: Admission D-dimer was associated with VTE diagnosis during hospitalization for COVID-19; however, prospective validation of this finding is needed to identify optimal D-dimer thresholds to guide VTE prophylaxis measures.

Indexed as

COVID‐19D‐dimerprognostic biomarkersvenous thromboembolismVTE

Identifiers

PMID36032214
PMCPMC9412137
OpenAlexW4293206452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.